Table 4.
Risk of human papillomavirus-related cancer among patients with end-stage renal disease by type of renal replacement therapy
| |
Dialysis |
Graft function |
|
|
||
|---|---|---|---|---|---|---|
| No. | IR (95% CI)a | No | IR (95%CI)a | IRR (95% CI) | P value | |
| Head and neckb |
8 |
21.4 (10.7-42.7) |
10 |
42.9 (23.1-79.6) |
2.00 (0.71-5.85) |
0.1 |
| Vulva and vagina |
5 |
35.0 (14.5-84.0) |
10 |
116 (62.3-215) |
3.31 (1.13-9.69) |
0.03 |
| Cervix |
8 |
55.9 (28.0-112) |
4 |
46.3 (17.4-123) |
0.83 (0.25-2.75) |
0.8 |
| Anal |
5 |
13.3 (5.55-32.1) |
7 |
30.0 (14.3-62.9) |
2.25 (0.71-7.08) |
0.2 |
| Penis |
3 |
13.0 (4.18-40.2) |
2 |
13.6 (3.40-54.4) |
1.05 (0.18-6.29) |
0.9 |
| All HPV-related | 29 | 77.4 (53.8-111) | 33 | 141 (100–198) | 1.83 (1.08-3.12) | 0.02 |
Abbreviations: No. number cancers, CI confidence interval, IR incidence rate, IRR unadjusted incidence rate ratio, IR incidence rate.
a Per 100,000 person-years.
b HPV-related head and neck cancer subsites as outlined in Table 1.